Juan C Sarmiento-Monroy
Juan C. is a Rheumatologist and clinical research fellow at the Hospital Clinic of Barcelona. His main research interests include the validation of biomarkers in RA-ILD and the development of digital tools for patients with SLE. Juan C. is a member of the EMEUNET Newsletter Sub-Committee.
| Poster 0251 | Sunday, 12.11.23 09.00 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I Author: Wei, J (China) Title: SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR INITIATION, RISK OF RECURRENT GOUT FLARES, AND MORTALITY IN PATIENTS WITH GOUT AND TYPE 2 DIABETES: A POPULATION-BASED COHORT STUDY  SGLT2i were associated with a lower risk of recurrent gout flares and mortality than their active comparators in patients with gout and type 2 diabetes. |
| Poster 0234 | Sunday, 12.11.23 09.00 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I Author: Tedeschi, S (USA) Title: IDENTIFYING OPTIMAL SERUM URATE LEVELS TO REDUCE GOUT FLARES IN PATIENTS TAKING URATE LOWERING THERAPY: A POST-HOC COHORT ANALYSIS OF CARES WITH CONSIDERATION OF DROP-OUT These data suggest a potential benefit of achieving very low SU levels (≤3.9 mg/dL) and consideration of a longer duration of prophylaxis to reduce gout flares. |
| Poster 0246 | Sunday, 12.11.23 09.00 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I Author: Baraf, H (USA) Title: SAFETY & EFFICACY OF SEL-212 IN PATIENTS WITH GOUT REFRACTORY TO CONVENTIONAL TREATMENT: PRIMARY OUTCOMES FROM TWO RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDIES Targeted immunomodulation with SEL-212 (tolerogenic nanoparticles containing rapamycin followed by pegadricase) has the potential to provide a new uricase-based treatment option for patients with gout refractory to conventional therapies. |
| Poster 0247 | Sunday, 12.11.23 09.00 Poster Session A: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I Author: Kluberg, S (USA) Title: RISK OF INCIDENT GOUT FOLLOWING EXPOSURE TO RECOMBINANT ZOSTER VACCINE IN ADULTS AGED ≥50 YEARS IN THE UNITED STATES This retrospective safety study found no evidence of a statistically significant increased risk of gout in the 30 days following recombinant zoster vaccine vaccination. |
| Oral 0813 | Sunday, 12.11.23 16.00 Metabolic & Crystal Arthropathies – Basic & Clinical ScienceSLE – Treatment II: Nonrenal Author: Andrés, M (Spain) Title: SONOGRAPHIC CRYSTAL DEPOSITS AND POWER-DOPPLER SIGNAL IN PATIENTS WITH GOUT FULFILLING REMISSION CRITERIA: A MULTICENTER STUDY ENROLLING 115 PARTICIPANTS Most patients with gout fulfilling remission criteria still show sonographic MSU crystal deposits and one-third, sonographic inflammation. |
| Poster 1888 | Tuesday, 14.11.23 09.00 Poster Session C: Imaging of Rheumatic Diseases Poster II Author: Yoo, W-H (South Korea) Title: SOLVING THE FINAL PUZZLE OF GOUT DETECTION IN DECT VIA MACHINE LEARNING-BASED MITIGATION OF PSEUDOLESION-RELATED CHALLENGES: ENHANCING DIAGNOSTIC ACCURACY Deep learning algorithms offer comprehensible and unequivocal approaches in DECT, allowing for precise and unmistakable diagnoses of gout. |